Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.

Kleiman LB, Maiwald T, Conzelmann H, Lauffenburger DA, Sorger PK.

Mol Cell. 2011 Sep 2;43(5):723-37. doi: 10.1016/j.molcel.2011.07.014.


Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.

Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT.

Neoplasia. 2001 Jul-Aug;3(4):339-50.


The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.

Bowers G, Reardon D, Hewitt T, Dent P, Mikkelsen RB, Valerie K, Lammering G, Amir C, Schmidt-Ullrich RK.

Oncogene. 2001 Mar 15;20(11):1388-97. Review. Erratum in: Oncogene 2001 Jun 28;20(29):3927.


ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.

Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE.

J Biol Chem. 1999 Jun 11;274(24):17209-18.


Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression.

Hart MR, Su HY, Broka D, Goverdhan A, Schroeder JA.

Mol Ther. 2013 Nov;21(11):1996-2007. doi: 10.1038/mt.2013.196.


AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.

Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D.

Clin Cancer Res. 2010 Feb 15;16(4):1159-69. doi: 10.1158/1078-0432.CCR-09-2353.


Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.

Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung HJ, Luciw PA.

Assay Drug Dev Technol. 2010 Feb;8(1):27-36. doi: 10.1089/adt.2009.0208.


ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW.

Clin Cancer Res. 2002 Oct;8(10):3054-64.


The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Review.


ErbB kinases and NDF signaling in human prostate cancer cells.

Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.

Oncogene. 1997 Nov 27;15(22):2705-16.


Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.

Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.

Mol Pharmacol. 2008 Feb;73(2):338-48.


Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.

Thelemann A, Petti F, Griffin G, Iwata K, Hunt T, Settinari T, Fenyo D, Gibson N, Haley JD.

Mol Cell Proteomics. 2005 Apr;4(4):356-76.


Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.

Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.

Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4.


Analysis of receptor tyrosine kinase (RTK) phosphorylation by immunoblotting.

McDermott M, O'Donovan N.

Methods Mol Biol. 2015;1233:3-14. doi: 10.1007/978-1-4939-1789-1_1.


BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells.

Egeblad M, Mortensen OH, van Kempen LC, Jäättelä M.

Biochem Biophys Res Commun. 2001 Feb 16;281(1):25-31.


Supplemental Content

Support Center